A5010245587- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
- Glioma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Lymphatic System and Diseases
- Cancer-related cognitive impairment studies
- Advanced Breast Cancer Therapies
- Brain Metastases and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Clinical practice guidelines implementation
- Artificial Intelligence in Healthcare and Education
- Exercise and Physiological Responses
- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Heart Failure Treatment and Management
- Health and Medical Studies
- Chronic Myeloid Leukemia Treatments
- AI in cancer detection
- Medical Practices and Rehabilitation
University Hospital Cologne
2014-2024
University of Cologne
2013-2024
Heinrich Heine University Düsseldorf
2022-2024
Düsseldorf University Hospital
2022-2024
Centrum für Integrierte Onkologie
2013-2023
TU Dortmund University
2021
Weatherford College
2021
German Cancer Research Center
2021
German Sport University Cologne
2021
Michael Foundation
2020
The objective of this trial was to evaluate safety and efficacy bendamustine combined with rituximab (BR) in patients relapsed and/or refractory chronic lymphocytic leukemia (CLL).Seventy-eight patients, including 22 fludarabine-refractory disease (28.2%) 14 (17.9%) deletion 17p, received BR chemoimmunotherapy. Bendamustine administered at a dose 70 mg/m(2) on days 1 2 375 day 0 the first course 500 during subsequent courses for up six courses.On basis intent-to-treat analysis, overall...
Abstract The evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown 1–3 . Here we determined tumour phylogenies at diagnosis throughout immunotherapy by multiregion sequencing 160 tumours from 65 patients. Treatment-naive SCLC exhibited clonal homogeneity distinct sites, whereas first-line platinum-based led a burst in genomic intratumour heterogeneity spatial diversity. We observed branched evolution shift...
To determine the efficacy and safety of a newly developed concomitant administration fludarabine alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL).A total 36 were treated this phase II study (median age, 61.47 years; mean number prior chemotherapies, 2.6; Binet stage C, n = 28). After an initial dose escalation over 3 days, 30 mg mg/m2 administered on consecutive days. Treatment was repeated after 28 days for up to six cycles. Restaging...
The prognosis of patients with central nervous system relapse aggressive lymphoma is very poor no therapy established so far. In a prospective multicenter phase II study, we evaluated potentially curative chemotherapy-only regimen in these patients. Adult immunocompetent 65 years age or under received induction chemotherapy MTX/IFO/DEP (methotrexate 4 g/m2 intravenously (i.v.) Day 1, ifosfamide 2 i.v. Days 3– 5 and liposomal cytarabine 50 mg intrathecally (i.th) 6) AraC/TT/DEP (cytarabine...
An allogeneic hematopoietic stem cell transplantation (HSCT) can have profound and lasting adverse effects on a patient's physical psychological well-being. So far, only few studies investigated the effectiveness of activity over entire inpatient phase an HSCT. Purpose: We performed randomized controlled study to examine influence moderate exercise program starting parallel chemotherapeutic conditioning total body irradiation constitution. Patients methods: Forty-seven patients undergoing...
High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis baseline risk factors patients with lymphoma who underwent treatment approach. We retrospectively analyzed 105 immunocompetent high-dose or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997...
To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures functions combination serum parameters neuroelectric recordings. Self-perceived status cognition, fatigue emotional functioning were reduced (n = 30) compared to healthy controls 10). Cognitive performance was impaired NHL a norm sample 1179). PCCI more severe treated rituximab bendamustine (BR) than who...
Physical activity is associated with decreased cancer (recurrence) risk and a reduction in treatment-specific side effects. Exercise modulates cytokine expression shows beneficial effects on patients' immune system. We investigated the following: (i) whether Non-Hodgkin-Lymphoma patients have increased serum macrophage migration inhibiting factor (MIF) Interleukin-6 (IL-6) levels after immunochemotherapy; (ii) physical influences levels; (iii) are histone modifications tumor-competitive...
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically relevant side effect of chemotherapy. Approximately 50% all leukemia, lymphoma, colorectal- breast cancer patients are affected. CIPN induced by neurotoxic chemotherapeutic agents can manifest with sensory and/or motor deficits. It associated significant disability poor recovery. Common symptoms include pain, altered sensation, reduced or absent reflexes, muscle weakness, balance control insecure gait. These not...